Pridopidine, Prilenia Therapeutics’ drug candidate for treating Huntington’s disease, and sebetralstat, KalVista Pharmaceuticals’ investigational oral, on-demand therapy for hereditary angioedema, are among the latest products that the European Medicines Agency has started reviewing for potential pan-EU marketing authorization.
Key Takeaways
- The European Medicines Agency started reviewing the EU marketing authorization applications for 10 new drugs on 15 August.
- The drugs comprise pridopidine, sebetralstat, mirdametinib, lifileucel, zuranolone, olezarsen, aflibercept, hydrocortisone and two denosumab products
Pridopidine, if approved, could become the first treatment for Huntington’s disease with the ability to impact progression, according to Prilenia
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?